TYK Medicines reports discovery of second-generation RET inhibitor with activity against multiple RET mutants
May 9, 2023
Researchers from TYK Medicines Inc. have reported the discovery and preclinical evaluation of TY-1091, a second-generation RET inhibitor being developed for the treatment of RET-mutant cancers.
